(Q40883797)

24 September 2017

title

Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol (English)

1 reference

24 September 2017

1 reference

Aigner A

1

1 reference

24 September 2017

Hsieh SS

series ordinal

2

1 reference

24 September 2017

Malerczyk C

series ordinal

3

1 reference

24 September 2017

Czubayko F

series ordinal

4

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

24 September 2017

1 reference

24 September 2017

volume

144

1 reference

24 September 2017

issue

1-3

1 reference

24 September 2017

page(s)

221-228

1 reference

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Neu and its ligands: from an oncogene to neural factors

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Heregulin induces tyrosine phosphorylation of HER4/p180erbB4

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0300-483X%2899%2900210-3

7 January 2021

10.1016/S0300-483X(99)00210-3

Identifiers

DOI

1 reference

24 September 2017

1 reference